Regen BioPharma Inc (RGBP)

[soupoftheday]

“Our filed IND # 16200 for dCellVax leverages dendritic cells that are modified outside of the body to trigger an immune response against breast cancer. In the newly filed patent application we cover means of activating dendritic cells inside the body, with the hope of stimulating T cell responses to clear prostate cancer,” said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma.

https://immuno-oncologynews.com/2015/09/22/regen-biopharma-inc-submits-utility-patent-application-for-immuno-oncology-treatment/